ArticleCancer management and research2019
The Characteristics and Survival of Patients with Mesorectum Metastatic Lymph Nodes from Cervical Cancer.
Article in Cancer management and research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A potential disease monitoring and prognostic biomarker in cervical cancer patients: The clinical application of circular RNA_0018289.Journal of clinical laboratory analysis · 2020Article
- Circ SMARCA5 Inhibited Tumor Metastasis by Interacting with SND1 and Downregulating the YWHAB Gene in Cervical Cancer.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo analyze the characteristics and survival of patients with mesorectum metastatic lymph nodes (MLNs) from cervical cancer. PATIENTS AND
methodsWe retrospectively reviewed 1194 consecutive patients with FIGO stage IA-IVA cervical cancer who were treated with definitive radiotherapy between January 2011 and December 2015 in our institute. Patients were treated with intensity-modulated radiation therapy (IMRT) and brachytherapy, combined with concurrent chemotherapy. Mesorectum, pelvic and para-aortic MLNs were boosted 59-61Gy with IMRT. We calculated the clinical characteristics and survival of the patients with and without mesorectum MLNs and made comparisons between them.
resultsThe incidence rate of mesorectum MLNs was 0.8% (10/1194). The incidence rates for patients with FIGO stages I, II, III, and IVA disease were 0%, 0.4%, 2.0%, and 33.3%, respectively. Mesorectum MLNs were associated with more advanced stage (p <0.001); larger tumor size (p = 0.002), para-aortic MLNs (p <0.001), common iliac MLNs (p <0.001), and bilateral pelvic MLNs (p <0.001). All patients with mesorectum MLNs experienced treatment failure and died during follow-up. The median overall survival was 10.43 months. The 2-year overall survival (OS), disease-free survival (DFS), and local control (LC) rates were 10%, 0%, and 30%, respectively. Multivariate analysis showed that that mesorectum MLNs (hazard ratio, HR 4.0, 95% CI 1.8-9.1, p=0.001), para-aortic MLNs (HR 1.8, 95% CI 1.1-2.8, p=0.017) and pelvic MLNs (HR 2.5, 95% CI 1.7-3.7, p<0.001) were independent prognostic factors of OS.
conclusionMesorectum MLNs from cervical cancer are rare. And, the survival of patients with mesorectum MLNs was poor after dose-escalated concurrent chemoradiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.